Cure My Disease

Don't miss your cure!

 Log in / Sign up

Brain tumor drug vorasidenib tested in everyday practice

NCT ID NCT06969352

Ongoing Disease control Sponsor: Servier (Tianjin) Pharmaceutical Co. LTD. Source: ClinicalTrials.gov ↗

First seen Jul 21, 2026 · Last updated Jul 22, 2026 · Updated 1 time

Summary

This study looks at how well the drug vorasidenib works and how safe it is for people with a slow-growing type of brain tumor called grade 2 astrocytoma or oligodendroglioma that has an IDH1 or IDH2 mutation. The study includes people aged 12 and older in China who are treated in regular medical practice, not in a strict research setting. Researchers will measure tumor growth over time and compare results to a group of similar patients who did not receive the drug.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance
vorasidenib
What this could lead to
If successful, this study could confirm that vorasidenib effectively slows tumor growth in routine clinical practice, offering a new treatment option for people with these slow-growing brain tumors.
What could go wrong
This is an observational real-world study, not a randomized controlled trial, so results may be less definitive. The small size (62 participants) and lack of mandatory visits could limit data quality.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for GLIOMAS are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

astrocytoma, IDH-mutant, grade 2 glioma oligodendroglioma, IDH-mutant and 1p/19q-codeleted grade 2

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

GLIOMAS

Contacts and locations

Locations

  • Beijing Tiantan Hospital, Capital Medical University

    Beijing, Beijing Municipality, China

  • West China Hospital Sichuan University

    Chengdu, Sichuan, China

  • West China Lecheng Hospital Sichuan University

    Qionghai, Hainan, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.